Please login to the form below

Not currently logged in
Email:
Password:

GSK’s Peter Harding appointed president of PAGB

Takes over from J&J’s Alex Pitt to lead UK consumer healthcare trade body

PAGB Peter HardingThe Proprietary Association of Great Britain (PAGB) has appointed GlaxoSmithKline's (GSK) general manager of UK consumer healthcare Peter Harding as its new president.

Harding (pictured right) was previously VP of the PAGB, which represents manufacturers of over-the-counter (OTC) medicines and food supplements, and takes over from outgoing president Alex Pitt who has recently moved to a new role in Switzerland with Johnson & Johnson (J&J).

“I am delighted that Peter has been willing to take on the role of PAGB president and I look forward to working with him to deliver the programmes that will help stimulate the development of the OTC market in the UK,” said PAGB's chief executive Sheila Kelly.

Harding joined GSK in 1997 and has previously served as general manager of its nutritional healthcare in the UK, working with GSK products including Ribena and Lucozade, before the nutritional business was merged with consumer healthcare.

“I'm very pleased to be taking up this role at a time when our industry continues to be faced with a lot of change,” said Harding.

“I'm very excited by the work programmes that we've put in place in 2012 and genuinely believe that these initiatives will contribute positively to driving innovation in our sector and growth in the market.“

20th September 2012

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics